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Abstract
Background: The efficacy of fluralaner for the treatment of Otodectes cynotis infestations in dogs and cats was
evaluated after oral (dogs) or topical administration (dogs and cats).
Twenty-four dogs and sixteen cats were experimentally infested with O. cynotis and randomly allocated to equal
sized groups (n = 8/group). Dog groups were treated once, either orally with fluralaner at a minimum dose of
25 mg/kg body weight, topically with fluralaner at a dose of 25 mg/kg body weight or topically with saline
solution (control). Cat groups were treated once, either topically with fluralaner at a dose of 40 mg/kg body
weight or topically with saline solution. Ears of all animals were examined otoscopically for live visible mites
and the amount of debris and cerumen before, and 14 and 28 days after treatment. Twenty-eight days after
treatment, animals were sedated and both ears were flushed to obtain the total number of live mites per
animal. The efficacy was calculated, based on the results of the ear flushing, by comparing mean live mite
counts in the fluralaner treated groups versus the saline solution treated group.
Results: A single topical treatment of cats with fluralaner reduced the mean mite counts by 100% (P < 0.001)
at 28 days after treatment. Similarly, a single oral or topical treatment of dogs with fluralaner reduced the
mean mite counts by 99.8% (P < 0.001) at 28 days after treatment. Cats treated topically with fluralaner had
no mites visible during otoscopic examination at either 14 or 28 days after treatment. All dogs treated orally
or topically with fluralaner had no mites visible during otoscopic examination at 28 days after treatment. At
14 days after treatment, only 1–2 mites were visible in three dogs (oral treatment: 2 dogs, topical treatment:
1 dog). All fluralaner-treated animals showed improvement in the amount of cerumen exudation compared
with observations performed before treatment. No treatment related adverse events were observed in any
dogs or cats enrolled in these studies.
Conclusions: In this study, fluralaner administered topically to cats and orally or topically to dogs was highly
effective against Otodectes cynotis mite infestations.
Keywords: Bravecto™, Bravecto™ spot-on solution, Cat, Chewable tablets, Dog, Ear mite, Efficacy, Fluralaner,
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Background
Otodectes cynotis (“ear mites”) are a common cause of
otitis externa, particularly in cats but also in other
animals, including dogs, ferrets, foxes and occasion-
ally humans [1–3]. These mites are non-burrowing
obligate parasites belonging to the family Psoroptidae
that live mainly on the horizontal and vertical ear
canal lining surfaces, but are also occasionally seen
on the body (e.g. head, feet and tip of the tail) [4].
The life-cycle occurs entirely within the ear, includes
four stages (egg, larvae, nymph, adult) and can be
completed in about 3 weeks [5].
Ear mite infestation (“otocariosis”) is very contagious
[6]; occurs in dogs and cats worldwide; and is commonly
diagnosed during routine veterinary physical examina-
tions. Up to 85% of otitis externa cases in cats and up to
50% of such cases in dogs are estimated to be caused by
O. cynotis [7]. Puppies and kittens, particularly cats
between 3–6 months of age [8], appear to be more com-
monly affected than older animals, possibly because of
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acquired immunity [6, 9]. The main route of infestation
is from infested dams/queens to their puppies/kittens,
but mites can also be spread by contaminated combs,
brushes, bedding and other grooming accessories [10].
Ear mites primarily feed on desquamated epithelial cells
and aural exudates but will occasionally pierce the ear
lining and feed on tissue fluids [11]. Otitis externa in
infested dogs and cats is characterized by vertical and
horizontal ear canal erythema with a characteristic dark
brown, ceruminous otic exudate. Papulocrustous lesions
(miliary dermatitis) may be found on the head, feet and
tip of the tail, if mites migrate out of the ear canal [12].
Clinical signs include marked pruritus, mild to severe
dermatitis, frequent scratching of the ears, and head
shaking. The intense pruritus may result in self-
mutilation, bleeding and aural haematoma development
[10]. Occasionally, the infestation leads to intense irrita-
tion and secondary bacterial infection, possibly resulting
in purulent otitis externa [13].
Fluralaner is an isoxazoline ectoparasiticide, that pro-
vides immediate and persistent efficacy against ectopara-
sites including ticks and fleas on dogs and cats [14].
Oral fluralaner treatment is effective against generalized
Demodex mite infestation on dogs [15] and oral and top-
ical fluralaner treatment are effective against Sarcoptes
scabei infestation on dogs [16], whereas there are no re-
ports regarding efficacy against mites on cats. Fluralaner
(Bravecto™) is commercially available as a chewable tablet
for dogs or as a spot-on solution for cats. A spot-on
solution is also licensed in some countries for use on dogs.
These fluralaner formulations were evaluated for treat-
ment of infestations with O. cynotis in dogs and cats.
Methods
Study set-up
Two studies, one in dogs and one in cats, were con-
ducted in accordance with Good Clinical Practice (VICH
guideline GL9, Good Clinical Practice, EMA, 2000). The
study set-up was a parallel group, masked, randomized,
and controlled efficacy design. Masking of the study
personnel was assured through the separation of study
functions, i.e. personnel conducting observations, animal
care or performing mite examinations and counts after
treatment were masked to treatment allocation.
Animal details
Dogs included were mixed breed (mainly mongrels) and
of both sexes (18 males, 6 females), between 1 and
9 years old and weighing between 8.8 and 24.2 kg on the
day of treatment. Cats included were European mixed
breed (short hair) and of both sexes (6 males, 10
females), between 10 weeks and 5 years old, and weighing
between 2.3 and 4.7 kg on the day of treatment.
Otodectes cynotis infestations were established in all
animals by harvesting mites by lavage from donor
animals and transferring approximately 50 to 100 mites,
depending on the intensity of infestation in donor
animals, into each ear of the recipient animal. Donor
animals were either naturally infested animals from the
field or experimentally infested animals from the test
site. Donor dogs were used for the dog study and donor
cats were used for the cat study. Animals used in the
study were experimentally infested within one month
prior to study start. Before study inclusion, the presence
of live O. cynotis mites in both ears was confirmed in
each animal by otoscopic examination. None of the
animals had been treated with fluralaner or any other
product with an acaricidal/insecticidal effect for at least
8 weeks prior to treatment. In each study, the animals
were blocked within sex by descending pre-treatment
live mite and debris score, randomly allocated to one of
three study groups in the dog study or to one of two
study groups in the cat study, with groups consisting of
eight animals each. All animals were healthy upon
physical examination, apart from otic signs of ear mite
infestation, prior to treatment.
For the duration of the study, dogs were housed indi-
vidually in an indoor/outdoor run, and cats were housed
in groups of 2–3 cats within their study group in an
outdoor pen. Physical contact between animals (dogs) or
animals of different groups (cats) was not possible. All
animals were fed a species specific food once a day,
according to the manufacturer’s recommendations and
had free access to potable municipal water.
Treatment
One group of dogs was treated once orally with fluralaner
chewable tablets, at the minimum recommended dose of
25 mg/kg body weight. Doses were determined based on
the individual body weights and the nominal content of
fluralaner in the tablets. Dogs received a single whole tab-
let or a combination of tablets to achieve a dose as close
as possible to the calculated target fluralaner dose without
underdosing (dose range 25.4–32.7 mg/kg body weight).
Chewable tablet(s) were administered 20 (±10) minutes
after food had been offered by placing the tablet(s) in the
back of the mouth over the tongue to initiate swallowing.
No vomiting or regurgitation was observed in any treated
dog. A second group of dogs was treated once topically
with fluralaner at a dose of 25 mg/kg body weight. One
group of cats was treated once topically with fluralaner at
a dose of 40 mg/kg body weight. Cats and dogs in the
control groups and dogs treated orally with fluralaner
chewable tablets were treated once topically with saline
solution, to maintain masking. The volume of saline
solution was equivalent to the volume of fluralaner
solution applied to the treated groups. Before topical
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administration of fluralaner or saline solution using a
disposable 1 ml plastic syringe, the skin and hair of
the designated administration site(s) were inspected
visually to confirm absence of any abnormalities. For
administration, the animal was held in a standing position,
the animal’s hair was parted and the tip of the syringe was
placed vertically on the skin and the fluralaner or saline
solution administered directly to the skin. Dogs and cats
were topically administered one or more spots according
to the product label administration recommendations. No
evidence of mis-dosing, such as spillage or run-off/drip-
off, was observed in any treated animal.
Assessment of mite infestation
An otoscopic examination of both ears from each animal
was performed prior to treatment and at 14 and 28 days
after treatment. At each otoscopic examination the num-
ber of visible live mites was counted in each ear, with
the following clustering of results: 0 live mites; 1–4 live
mites; 5–10 live mites; or > 10 live mites. For study
inclusion, an animal was regarded as adequately infested
if there were > 10 live mites in each ear. Additionally, at
the same time points, the amount of debris/cerumen in
each ear was recorded as no debris/cerumen, slight
debris/cerumen, moderate debris/cerumen, or severe
debris/cerumen.
Twenty eight days after treatment, animals were
sedated and both ears were flushed to determine the
number of live mites. The ear duct was filled with 5%
aqueous solution of docusate sodium (Docusol®, 5%
aqueous solution of docusate sodium, Kyron Laboratories)
and slightly massaged to soften the ear duct content. The
solution was removed from the ears and filtered through a
38 μm sieve. The ears were then flushed with lukewarm
saline solution, which was poured through the same sieve.
The ears were examined otoscopically and, if needed, the
flushing process was repeated until the ear ducts were
assessed as clean (no visible cerumen or mites). Sieve
contents were rinsed with water and transferred to a Petri
dish and all live mites (adults, larvae, nymphs) were
counted under a stereo microscope.
Animal health
General health observations were performed once daily
throughout the complete study duration.
Efficacy evaluation
Statistical analysis was performed using the software
package SAS® (SAS Institute Inc., Cary, NC, USA,
release 9.3 TS Level 1 M2), using the individual animal
as experimental unit. The primary assessment variable in
each study was the total number of live mites (sum of
adults, nymphs and larvae from both ears) counted during
ear flushing on Day 28 after treatment. The percentage of
efficacy against O. cynotis mites was calculated using
geometric means employing Abbott’s formula:
Efficay %ð Þ ¼ 100 MC MTð Þ;
where MC was the mean number of total live mite
counts in the saline treated group, and MT the mean
number of total live mite counts in each fluralaner-
treated group. Significant differences were assessed
between the log-transformed [ln(x + 1)] counts of live O.
cynotis mites in the fluralaner treated groups compared
to the log-transformed [ln(x + 1)] counts of the saline
treated group using a mixed analysis variance model
including study group as a fixed effect and block as a
random effect. The two-sided level of significance was set
as P ≤ 0.05 (One-way ANOVA with a treatment effect).
Results
No adverse events related to oral or topical fluralaner
administration were observed in any cat or dog at any
time during the studies.
All included dogs had an adequate mite infestation in
both ears, except for one dog that had an otoscopic mite
count of 5–10 mites in one ear. However, this dog had a
severe debris/cerumen build up in both ears and > 10
live mites in the other ear and it was therefore judged as
adequately infested for inclusion. From the included
cats, 9 cats had an adequate mite infested in both ears, 5
cats had an otoscopic mite count of > 10 mites in one
ear and between 1–10 mites in the other ear and two
cats had an otoscopic mite count of 1–4 mites in both
ears. Nevertheless, due to the presence of debris/ceru-
men, all cats were judged to be adequately infested and
included into the study.
In cats, after ear flushing 28 days after treatment, no
mites were observed in any fluralaner treated animal,
whereas a mean of 595.1 live mites was recorded in
Table 1 Mite counts and corresponding efficacy (%) of fluralaner
administered once topically (cats and dogs) or orally (dogs)
against infestations with O. cynotis at 28 days after treatment
Range (n) Mean (n)a Efficacy (%)
Cats
Topical treatment 0 0 100 (P < 0.0001b)
Negative control 6–1,843 197.5 na
Dogs
Topical treatment 0–1 0.1 99.8 (P < 0.0001c)
Oral treatment 0–1 0.1 99.8 (P < 0.0001d)
Negative control 24–664 58.9 na
Abbreviation: na not applicable
aGeometric mean
bOne-way ANOVA with a treatment effect (F(2, 21) = 58.44)
cOne-way ANOVA with a treatment effect (F(2, 21) = 100.07)
dOne-way ANOVA with a treatment effect (F(2, 21) = 100.07)
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control cats, thus resulting in a significant (P < 0.001)
mite reduction and efficacy of 100% (Table 1). Cats
treated topically with fluralaner had no mites visible
during otoscopic examination at either 14 or 28 days after
treatment (Fig. 1). Fluralaner treated cats showed
improvement in the amount of cerumen/debris by 28 days
after treatment (Fig. 2).
In dogs, after ear flushing 28 days after treatment, one
animal in the topical fluralaner and one in the oral flura-
laner treated group was found with one live adult mite
in one ear, whereas a mean of 58.9 live mites was
recorded in control dogs. The calculated efficacy was
therefore 99.8% (statistically significant, P ≤ 0.001), for
both, orally and topically fluralaner-treated dogs (Table 1).
All dogs treated orally or topically with fluralaner had no
mites visible during otoscopic examination at 28 days after
treatment. At 14 days after treatment, only 1–2 mites were
visible in three dogs (oral treatment: 1 dog with 1 mite, 1
dog with 2 mites; topical treatment: 1 dog with 1 mite),
whereas all other dogs had no visible mites (Fig. 3).
Improvement in the amount of cerumen/debris was
observed in both orally and topically fluralaner-treated
groups by 28 days after treatment (Fig. 4).
Discussion
Topical fluralaner administration completely eliminated
ear mites from infested cats, and both, oral and topical
fluralaner administration, was 99.8% effective against ear
mite infestations in dogs at 28 days after treatment. At
14 days after treatment, no mites were visible during
otoscopic examination of any cat and only one mite was
visible in one dog (topical treatment) or two mites in
two dogs (oral treatment) were visible. This immediate
mite decrease was observed together with improvement
of otic clinical signs seen in both dogs and cats after
fluralaner treatment. The study observation period was
28 days; however, the duration of efficacy of fluralaner
against other ectoparasites is up to 12 weeks [14] and
therefore it is assumed that efficacy and further improve-
ment of otic signs will continue beyond this study period.
Fig. 1 Cats with visible live mites observed during otoscopic examinations before and 14 and 28 days after treatment
Fig. 2 Cats with cerumen/debris observed during otoscopic examinations before and 14 and 28 days after treatment
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Fluralaner efficacy against cutaneous mites is likely
associated with the presence of fluralaner in extracellular
fluids found in the dermal tissues. Fluralaner (Bravecto™)
is effective against other cutaneous mite infestations
of dogs including generalized demodicosis [15] and
sarcoptic mange [16]. This is the first study showing
efficacy of fluralaner treatment against a mite infest-
ation of cats.
Ear mite infestations are of greater clinical importance
in cats than in dogs. Control cats showed a tenfold higher
number of mites compared to control dogs at the end of
the 28 day observation period, although all animals were
initially experimentally infested with the same number of
mites.
Existing commercially available products for the treat-
ment of Otodectes cynotis infestation in dogs and cats
either consist of one (selamectin) or a combination of two
(imidacloprid and moxidectin) pharmaceutical ingredients.
Efficacy over 4 weeks of these products is reported follow-
ing either a single administration [9, 17] or two administra-
tions one month apart [9, 13, 17, 18]. The efficacy results,
assessed one month after treatment, are in line with the
results shown here after a single treatment of dogs and cats
with fluralaner.
The 28 day period in this study protocol between
treatment of dogs and cats and the subsequent assess-
ment of clinical signs was too short to allow complete
resolution of ear mite associated presence of debris and
cerumen. Fluralaner treatment provides systemic ecto-
parasiticide efficacy for up to 12 weeks against ticks and
fleas on dogs and cats [14] and therefore fluralaner
administration might provide sustained control of ear
mite infestations in susceptible dogs and cats following
treatment. Fluralaner could provide a convenient option
Fig. 3 Dogs with visible live mites observed during otoscopic examinations before and 14 and 28 days after treatment
Fig. 4 Dogs with cerumen/debris observed during otoscopic examinations before and 14 and 28 days after treatment
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to provide resolution of ear mite infestations in addition
to its immediate and persistent activity against fleas,
ticks and mange mites on treated dogs and cats.
Conclusions
Topical administration of fluralaner was 100% effective
for elimination of ear mites infestations in cats, and oral
and topical fluralaner administration are 99.8% effective
against ear mites in dogs 28 days after treatment. In
both studies, fluralaner treatment resulted in an
improvement of otic clinical signs during the 28 day
observation period.
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